US9849244B2 - Dose setting mechanism for priming a drug delivery device - Google Patents
Dose setting mechanism for priming a drug delivery device Download PDFInfo
- Publication number
- US9849244B2 US9849244B2 US13/320,639 US201013320639A US9849244B2 US 9849244 B2 US9849244 B2 US 9849244B2 US 201013320639 A US201013320639 A US 201013320639A US 9849244 B2 US9849244 B2 US 9849244B2
- Authority
- US
- United States
- Prior art keywords
- dose
- cartridge holder
- coupling part
- cartridge
- setting mechanism
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active, expires
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31525—Dosing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
- A61M2005/2403—Ampoule inserted into the ampoule holder
- A61M2005/2407—Ampoule inserted into the ampoule holder from the rear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
- A61M2005/2485—Ampoule holder connected to rest of syringe
- A61M2005/2488—Ampoule holder connected to rest of syringe via rotation, e.g. threads or bayonet
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
- A61M2005/2485—Ampoule holder connected to rest of syringe
- A61M2005/2492—Ampoule holder connected to rest of syringe via snap connection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/3129—Syringe barrels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/3146—Priming, e.g. purging, reducing backlash or clearance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31533—Dosing mechanisms, i.e. setting a dose
- A61M5/31535—Means improving security or handling thereof, e.g. blocking means, means preventing insufficient dosing, means allowing correction of overset dose
- A61M5/31543—Means improving security or handling thereof, e.g. blocking means, means preventing insufficient dosing, means allowing correction of overset dose piston rod reset means, i.e. means for causing or facilitating retraction of piston rod to its starting position during cartridge change
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31533—Dosing mechanisms, i.e. setting a dose
- A61M5/31545—Setting modes for dosing
- A61M5/31548—Mechanically operated dose setting member
- A61M5/3155—Mechanically operated dose setting member by rotational movement of dose setting member, e.g. during setting or filling of a syringe
- A61M5/31551—Mechanically operated dose setting member by rotational movement of dose setting member, e.g. during setting or filling of a syringe including axial movement of dose setting member
Definitions
- the present patent application is generally directed to drug delivery devices. More particularly, the present patent application is generally directed to drug delivery devices, such as pen type drug delivery devices. Such devices provide for self administration of medicinal product from a multi-dose cartridge and permit a user to set the delivery dose.
- the present application may find application in both resettable (i.e., reusable) and non-resettable (i.e., non-reusable) type drug delivery devices. However, aspects of the invention may be equally applicable in other scenarios as well.
- Pen type drug delivery devices have application where regular injection by persons without formal medical training occurs. This is increasingly common among patients having diabetes where self-treatment enables such patients to conduct effective management of their disease.
- cartridges of medication are used. These cartridges are housed in a cartridge holder or cartridge housing. Such cartridges include a bung or stopper at one end. At the other end of the cartridge, the cartridge may comprise a pierceable seal.
- the medication delivery device has a dose setting mechanism that uses a spindle to move in a distal direction towards the cartridge and to press a distal end of the spindle against the bung. This expels a certain set or preselected dose of medication from the cartridge. In order to insure dose accuracy, it is important that the distal end of the spindle remains on the bung of the cartridge before, during and after injection of a dose of medicament.
- One perceived disadvantage of certain known medication delivery devices is that because of the various tolerance differences that may occur during manufacturing (e.g., tolerance differences that may arise during component molding) of the various parts making up the drug delivery device and the desire to not pre-load the bung axially in the assembled device, there may be a gap between the end of the spindle and the cartridge bung after the medication delivery device has been assembled. In other words, when initially assembled, the cartridge (and hence cartridge bung) may not be in contact with the distal end of the spindle. Therefore, if a user using the drug delivery device for the first time dials a dose, the actual dose received may be equal to the dialed dose less the initial gap between the distal end of the spindle and cartridge bung.
- the air gap between the cartridge bung and distal end of the spindle may be equivalent to a dose that causes the received dose that is outside preferred dose accuracy limits.
- this air gap may be equivalent to the loss of between 0 and 10 units (i.e., 0-0.14 milliliters) of drug product on the first dose.
- a device as defined in claims 1 and 10 which requires a rotational movement of a cartridge holder to prime the device and/or to bring the device in a condition allowing setting of a dose.
- the condition allowing setting of a dose is the primed condition of the device.
- a drug delivery device comprises a dose setting mechanism comprising a spindle.
- a cartridge holder is coupled to the dose setting mechanism.
- the cartridge holder comprises a cartridge having a movable bung at one end of the cartridge.
- the cartridge holder is rotated before a dose may be set with the dose setting mechanism.
- the cartridge holder must be rotated less than 360 degrees before a dose may be set with the dose setting mechanism.
- the cartridge holder must be rotated with respect to the dose setting mechanism before the dose may be set with the dose setting mechanism.
- rotation of the cartridge holder may prime the drug delivery device.
- rotation of the cartridge holder moves the spindle into an abutting engagement with the bung of the cartridge.
- the cartridge holder is rotationally locked to the dose setting mechanism.
- This rotationally locking of the cartridge holder to the dose setting mechanism may be by way of a one way, non-return detent feature.
- the cartridge holder provides a visual indication that the cartridge holder must be rotated before the dose may be set by the dose setting mechanism.
- the drug delivery device may either be a resettable drug delivery device or a not-resettable (disposable) drug delivery device.
- drug or “medicinal product” or “medicament”, as used herein, mean a pharmaceutical formulation containing at least one pharmaceutically active compound
- the pharmaceutically active compound has a molecular weight up to 1500 Da and/or is a peptide, a proteine, a polysaccharide, a vaccine, a DNA, a RNA, a antibody, an enzyme, an antibody, a hormone or an oligonucleotide, or a mixture of the above-mentioned pharmaceutically active compound,
- the pharmaceutically active compound is useful for the treatment and/or prophylaxis of diabetes mellitus or complications associated with diabetes mellitus such as diabetic retinopathy, thromboembolism disorders such as deep vein or pulmonary thromboembolism, acute coronary syndrome (AC S), angina, myocardial infarction, cancer, macular degeneration, inflammation, hay fever, atherosclerosis and/or rheumatoid arthritis,
- diabetes mellitus or complications associated with diabetes mellitus such as diabetic retinopathy, thromboembolism disorders such as deep vein or pulmonary thromboembolism, acute coronary syndrome (AC S), angina, myocardial infarction, cancer, macular degeneration, inflammation, hay fever, atherosclerosis and/or rheumatoid arthritis,
- diabetes mellitus or complications associated with diabetes mellitus such as diabetic retinopathy, thromboembolism disorders such as deep vein or pulmonary thromboembolism, acute
- the pharmaceutically active compound comprises at least one peptide for the treatment and/or prophylaxis of diabetes mellitus or complications associated with diabetes mellitus such as diabetic retinopathy,
- the pharmaceutically active compound comprises at least one human insulin or a human insulin analogue or derivative, glucagon-like peptide (GLP-1) or an analogue or derivative thereof, or exedin-3 or exedin-4 or an analogue or derivative of exedin-3 or exedin-4.
- GLP-1 glucagon-like peptide
- Insulin analogues are for example Gly(A21), Arg(B31), Arg(B32) human insulin; Lys(B3), Glu(B29) human insulin; Lys(B28), Pro(B29) human insulin; Asp(B28) human insulin; human insulin, wherein proline in position B28 is replaced by Asp, Lys, Leu, Val or Ala and wherein in position B29 Lys may be replaced by Pro; Ala(B26) human insulin; Des(B28-B30) human insulin; Des(B27) human insulin and Des(B30) human insulin.
- Insulin derivates are for example B29-N-myristoyl-des(B30) human insulin; B29-N-palmitoyl-des(B30) human insulin; B29-N-myristoyl human insulin; B29-N-palmitoyl human insulin; B28-N-myristoyl LysB28ProB29 human insulin; B28-N-palmitoyl-LysB28ProB29 human insulin; B30-N-myristoyl-ThrB29LysB30 human insulin; B30-N-palmitoyl-ThrB29LysB30 human insulin; B29-N-(N-palmitoyl-Y-glutamyl)-des(B30) human insulin; B29-N-(N-lithocholyl-Y-glutamyl)-des(B30) human insulin; B29-N-( ⁇ -carboxyheptadecanoyl)-des(B30) human insulin and B29-N-( ⁇ -carboxy
- Exendin-4 for example means Exendin-4(1-39), a peptide of the sequence H-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2.
- Exendin-4 derivatives are for example selected from the following list of compounds:
- Hormones are for example hypophysis hormones or hypothalamus hormones or regulatory active peptides and their antagonists as listed in Rote Liste, ed. 2008, Chapter 50, such as Gonadotropine (Follitropin, Lutropin, Choriongonadotropin, Menotropin), Somatropine (Somatropin), Desmopressin, Terlipressin, Gonadorelin, Triptorelin, Leuprorelin, Buserelin, Nafarelin, Goserelin.
- Gonadotropine Follitropin, Lutropin, Choriongonadotropin, Menotropin
- Somatropine Somatropin
- Desmopressin Terlipressin
- Gonadorelin Triptorelin
- Leuprorelin Buserelin
- Nafarelin Goserelin.
- a polysaccharide is for example a glucosaminoglycane, a hyaluronic acid, a heparin, a low molecular weight heparin or an ultra low molecular weight heparin or a derivative thereof, or a sulphated, e.g. a poly-sulphated form of the above-mentioned polysaccharides, and/or a pharmaceutically acceptable salt thereof.
- An example of a pharmaceutically acceptable salt of a poly-sulphated low molecular weight heparin is enoxaparin sodium.
- Pharmaceutically acceptable salts are for example acid addition salts and basic salts.
- Acid addition salts are e.g. HC1 or HBr salts.
- Basic salts are e.g. salts having a cation selected from alkali or alkaline, e.g. Na+, or K+, or Ca2+, or an ammonium ion N+(R1)(R2)(R3)(R4), wherein R1 to R4 independently of each other mean: hydrogen, an optionally substituted C1-C6-alkyl group, an optionally substituted C2-C6-alkenyl group, an optionally substituted C6-C10-aryl group, or an optionally substituted C6-C10-heteroaryl group.
- solvates are for example hydrates.
- a priming mechanism for a drug delivery device comprises a dose setting mechanism.
- the dose setting mechanism comprises a spindle and a dose dial sleeve.
- a cartridge holder comprises a cartridge comprising a movable bung and a pierceable seal.
- a coupling part connects the cartridge holder to the dose dial sleeve.
- a spindle nut rotationally coupled to the coupling part, couples the cartridge holder to the spindle.
- the coupling part which may comprise a thin metal pressing and/or a rigid coupling component, unlocks the dose dial sleeve so that the dose dial sleeve may be rotated to set a dose.
- the dose setting mechanism comprises at least one flexible locking element.
- the coupling part When the cartridge holder is rotated, the coupling part also rotates to thereby release said flexible locking element and allowing the dose dial sleeve to rotate and allow a user of the medical delivery device to set a dose.
- the spindle nut may further comprise a plurality of helical ramps.
- the plurality of helical ramps drive the spindle nut in a distal direction when the cartridge holder is rotated so that the spindle abuts a first surface of the bung.
- FIG. 1 illustrates an arrangement of a drug delivery device in accordance with the one aspect of the present invention
- FIG. 2 illustrates the drug delivery device of FIG. 1 with a cap removed and with a dose having been selected
- FIG. 3 illustrates a close up view of a drug delivery device before a priming step, such as the drug delivery device illustrated in FIG. 1 ;
- FIG. 4 illustrates a close up view of the drug delivery device illustrated in FIG. 3 after completion of a priming step
- FIG. 5 illustrates a close up view of a connection between a dose setting mechanism and cartridge housing of a drug delivery device in a non-priming state, such as drug delivery device illustrated in FIGS. 3 and 4 ;
- FIG. 6 illustrates a close up view of the connection between the dose setting mechanism and the cartridge illustrated in FIG. 5 , in a priming state
- FIG. 7 illustrates a close up view of a proximal end of the cartridge housing illustrated in FIGS. 5 and 6 , including a coupling part;
- FIG. 8 illustrates how the coupling part illustrated in FIG. 7 may be used to engage a dose dial sleeve of a dose setting mechanism, such as the dose setting mechanism illustrated in FIGS. 5 and 6 ;
- FIG. 9 illustrates the coupling part illustrated in FIG. 8 in a non-primed state
- FIG. 10 illustrates the coupling part illustrated in FIG. 9 in a primed state
- FIG. 11 illustrates a close up view of the stop faces provided along the distal end of the dose dial sleeve illustrated in FIG. 10 ;
- FIG. 12 illustrates a spindle nut that may be used to couple the coupling part to a dose setting member and to a cartridge housing;
- FIG. 13 illustrates the spindle nut coupled to the coupling part and dose dial sleeve of a dose setting mechanism.
- the drug delivery device 1 comprises a housing having a first cartridge retaining part 2 , and a dose setting mechanism 4 .
- the drug delivery device may be a resettable drug delivery device (i.e., a reusable device) or alternatively a non-resettable drug delivery device (i.e., a non-reusable device).
- a first end of the cartridge retaining part 2 and a second end of the dose setting mechanism 4 are secured together by connecting features.
- these connecting features would be permanent and non-reversible.
- resettable devices these connecting features would be releasable.
- the cartridge housing 2 is secured within the second end of the dose setting mechanism 4 .
- a removable cap 3 is releasably retained over a second end or distal end of a cartridge retaining part or cartridge housing.
- the dose setting mechanism 4 comprises a dose dial grip 12 and a window or lens 14 .
- a dose scale arrangement 16 is viewable through the window or lens 14 .
- FIG. 2 illustrates the medical delivery device 1 of FIG. 1 with the cover 3 removed from a distal end 19 of the medical delivery device 1 . This removal exposes the cartridge housing 6 .
- a cartridge 25 from which a number of doses of a medicinal product may be dispensed is provided in the cartridge housing 6 .
- the cartridge 25 contains a type of medicament that can be administered relatively often, such as once or more times a day.
- One such medicament is either long acting or short acting insulin or an insulin analog.
- the cartridge 25 comprises a bung or stopper (not illustrated in FIG. 2 ) that is retained near a second end or a proximal end 33 of the cartridge 25 .
- the medical delivery device also comprises a driver having a spindle (not illustrated in FIG. 2 ). As discussed above, before the device is primed, there may or may not be a gap between the end of the spindle and the cartridge bung.
- the cartridge housing 6 has a distal end 23 and a proximal end 27 .
- the cartridge distal end 23 of the cartridge housing 6 comprises a groove 8 for attaching a removable needle assembly.
- other needle assembly connection mechanisms could also be used.
- the drug delivery device 1 comprises a resettable device
- the cartridge proximal end 27 is removably connected to the dose setting mechanism 4 .
- cartridge housing proximal end 27 is removably connected to the dose setting mechanism 4 via a bayonet connection.
- other types of removable connection methods such as threads, partial threads, ramps and detents, snap locks, snap fits, and luer locks may also be used.
- the dose setting mechanism 4 of the drug delivery device illustrated in FIG. 2 may be utilized as a reusable drug delivery device. (i.e., a drug delivery device that can be reset) Where the drug delivery device 1 comprises a reusable drug delivery device, the cartridge 25 is removable from the cartridge housing 6 . The cartridge 25 may be removed from the device 1 without destroying the device 1 by merely having the user disconnect the dose setting mechanism 4 from the cartridge housing 6 .
- a user can attach a suitable needle assembly to the groove 8 provided at the distal end 23 of the cartridge housing 6 .
- a suitable needle assembly may be, for example, screwed onto a distal end 23 of the housing 6 or alternatively may be snapped onto this distal end 23 .
- the replaceable cap 3 may be used to re-cover the cartridge housing 6 .
- the outer dimensions of the replaceable cap 3 are similar or identical to the outer dimensions of the dose setting mechanism 4 so as to provide an impression of a unitary whole when the replaceable cap 3 is in position covering the cartridge housing 6 when the device is not in use.
- the drug delivery device 1 preferably forces a user to prime the device before they are permitted to select the first dose.
- the process of forcing a user to prime the cartridge before they can select and dispense the first dose reduces a potential risk of injecting the prime dose.
- forced priming is particularly advantageous for disposable devices where there is oftentimes a gap between a distal end of the spindle and the cartridge bung before the device is used. This gap is a consequence of the tolerances associated with the assembled parts as well as the desire not to pre-load the bung axially in the assembled device.
- the drug delivery device achieves this by the user rotating the cartridge holder relative to the housing in order to both prime the device and also to unlock the number sleeve so the user can subsequently rotate the dose dial sleeve to set the first dose.
- the cartridge holder is locked rotationally and therefore cannot be rotated with respect to the dose setting mechanism.
- FIG. 3 illustrates a close up view of a drug delivery device 50 before a priming step, such as the drug delivery device 1 illustrated in FIG. 1 .
- FIG. 4 illustrates a close up view of the drug delivery device 50 illustrated in FIG. 3 after completion of a priming step.
- the drug delivery device 50 comprises a dose setting mechanism 52 coupled to a cartridge housing 54 .
- this coupling mechanism comprises a releasable coupling mechanism (i.e., a thread, a bayonet lock, a luer lock, a snap fit or snap lock, etc.)
- this coupling this coupling mechanism comprises a non-reversible coupling mechanism.
- the dose setting mechanism 52 comprises various markings and indications along an outer surface 53 .
- this marking comprises a marking indicating a locked position (i.e., un-primed state) 58 and a marking indicating an unlocked position (i.e., primed state) 62 .
- various intermediate markings 59 are provided between the locked and unlocked position markings 58 , 62 , respectively.
- the cartridge housing 54 comprises markings along its outer surface 63 and these markings include a positional indicator (i.e., an arrow) 56 that is used to indicate the relative position of the cartridge housing 54 with respect to the outer surface 53 of the dose setting mechanism 52 .
- a positional indicator i.e., an arrow
- the cartridge housing 54 is rotated in direction of arrow 60 .
- the cartridge housing 54 is rotated in the direction of arrow 60 with respect to the dose setting mechanism 52 so that the arrow 56 moves from the locked marking 58 and then aligns with the unlocked designation 62 , as shown in FIG. 4 .
- the drug delivery device 50 now resides in a primed state.
- the spindle contained in the dose setting mechanism 52 now resides adjacent or abuts the bung provided in the cartridge of the cartridge housing 54 .
- the drug delivery device 50 is also now unlocked so that the dose setting mechanism 52 may now be used to set a dose (as illustrated in FIG. 2 ).
- the cartridge holder 54 is also rotationally locked and can therefore no longer be rotated with respect to the dose setting mechanism 52 .
- FIG. 5 illustrates a close up view of a connection between a dose setting mechanism and cartridge housing of a drug delivery device 70 , such as drug delivery device 50 illustrated in FIGS. 3 and 4 .
- the drug delivery device 70 is in a pre-primed state. Therefore, with the drug delivery device illustrated in FIG. 5 , a user could not set a dose until the device is primed.
- the dose setting mechanism 74 is rotationally coupled to the cartridge housing 72 .
- the cartridge housing 72 comprises a rib 76 that engages with an internally formed cavity on an inner surface of the dose setting mechanism 74 .
- This configuration allows for relative rotational movement only between the dose setting mechanism 74 and the cartridge housing 76 and no axial movement. This rotational relative movement occurs when the cartridge holder 72 is rotated from the locked position (i.e., FIG. 5 ) to the unlocked position (i.e., FIG. 6 ).
- FIG. 7 illustrates a close up view of a proximal end 68 of the cartridge housing 72 illustrated in FIGS. 5 and 6 .
- FIG. 7 also illustrates a coupling part 80 that may be used to couple the cartridge housing 72 to a dose setting mechanism, such as the dose setting mechanism 74 illustrated in FIGS. 5 and 6 .
- this cartridge housing 72 comprises an L shaped cavity 73 provided along a first outer surface 75 of the cartridge housing 72 . As described with respect to FIGS. 5 and 6 and as will be described in greater detail below, this cavity 73 is used to engage a portion of a coupling part so as to allow relative rotation between the cartridge holder 72 and the dose setting mechanism.
- coupling part 80 comprises a thin metal pressing.
- the coupling part 80 comprises a first set of axial projecting members 82 a , 82 b that project in an axial direction towards the distal end 69 of the cartridge housing 72 . These projecting members 82 a , 82 b rotationally affix or engage a first portion 75 of the cavity 73 .
- the coupling part 80 rotationally couples to a spindle nut and therefore a spindle of a dose setting mechanism and also acts upon a dose dial sleeve of the dose setting mechanism.
- the coupling part 80 further comprises a second set of axial projecting members 86 a , 86 b .
- This second set of projecting members 86 a , 86 b extend in a proximal direction away from the proximal end 68 of the cartridge housing 72 .
- This second set of projecting members 86 a , 86 b engage a portion of the dose setting mechanism, specifically an inner housing of the dose setting mechanism.
- the coupling part 80 further comprises two inwardly extending arms 84 a , 84 b that engage a spindle nut of the dose setting mechanism.
- FIG. 8 illustrates how the coupling part 80 illustrated in FIG. 7 may be used to engage an inner housing 92 of a dose setting mechanism, such as the dose setting mechanism illustrated in FIGS. 5 and 6 .
- the inner housing 92 comprises a first and a second flexible locking elements 98 a , 98 b located near a distal end 93 of the inner housing 92 .
- a circular shaped housing portion 94 is also near this distal end 93 .
- This housing portion 94 defines a cavity portion 101 having an inner surface and along this inner surface there are two internally radially directed recesses 96 a and 96 b.
- the coupling part 80 will be positioned to slide into the cavity 101 of the housing portion 94 such that the second set of protruding members 86 a , 86 b of the coupling part 80 slide through recesses 96 a , 96 b of the housing portion 94 , respectively.
- the second members 86 a , 86 b will then be positioned to reside over an external surface of the inner housing flexible elements 98 a , 98 b , respectively.
- the drug delivery device will not be primed but rather the dose dial sleeve 103 will be locked out and prevented from rotating.
- a user of such a drug delivery device will be prevented from selecting a dose, that is, the user will be prevented from rotating the dose dial sleeve 103 before the user has under taken a drug delivery device priming step.
- FIG. 9 illustrates the coupling part 80 engaged with the distal end 93 of the inner housing 92 .
- the coupling part 80 is in an initial position or in a non-primed state, before device priming occurs.
- the set of protruding elements 86 a , 86 b reside over the surface of the flexible elements 98 a , and 98 b , respectively. Therefore, when a cartridge holder is connected to the housing and is rotated (as illustrated in FIGS. 4 and 5 ), the coupling part 80 also rotates.
- FIG. 10 illustrates the coupling part 80 and inner housing 92 after rotating the coupling part to release the flexible locking elements and thereby completing of the priming step.
- the coupling part 80 has been rotated to a final or stop position 102 and the coupling part 80 has now been is rotated less than 360 degrees so as to push the inner housing flexible elements 98 a , 98 b radially inward.
- FIG. 11 illustrates a close up view of the stop faces 106 a , 106 b provided along the distal end of the inner housing 92 .
- the dose dial sleeve 103 is also illustrated with a scale arrangement 104 provided along an outer surface of this dose dial sleeve 103 .
- the dose dial sleeve 103 has mating stop faces 97 a , 97 b that engage with stop faces 106 a , 106 b on the inner housing.
- a spindle nut 114 is coupled to the coupling part 80 so that when the coupling part 80 rotates the spindle nut 114 rotates to drive a spindle 124 distally.
- this spindle nut 114 is circular in shape and comprises a first and a second helical ramp 116 a , 116 b .
- the spindle nut 114 further comprises a circular cavity having a male groove member 118 .
- the first and second helical ramps 116 a , 116 b serve to drive the spindle nut 114 in a distal direction (i.e., towards the injection site) when the cartridge holder is rotated.
- these helical ramps lock the cartridge holder rotationally at the end of the priming step.
- the helical ramps are detented so as to allow the cartridge housing 72 to be rotated back and removed to enable a new cartridge to be fitted.
- the height of the helical ramps 116 a , 116 b help to offset any slack in the drive mechanism that drives the spindle of the dose setting mechanism forwards to dispense a dose. In this manner, rotating the cartridge holder is generally equivalent to pressing on a dose button of the dose setting mechanism so as to take up slack in the drive mechanism.
- FIG. 13 illustrates the spindle nut 114 coupled to the coupling part 80 and inner housing 92 of a dose setting mechanism.
- the coupling part 80 is rotated by the cartridge holder (not illustrated). This in turn rotates the spindle nut 114 .
- this spindle has at least two overlapping grooves.
- one of these grooves 130 is engaged with a portion of the drug delivery device and could be either helical or axially extending along its length.
- the spindle 124 is threaded to a portion of the drug delivery device, as the spindle nut 114 rotates, it advances the spindle 124 axially in the distal direction D 2 128 so as to prime the drug delivery device.
- the rotation of the cartridge housing also unlocks the dose dial sleeve 103 to allow a user to now set a first dose of medication for the drug delivery device.
Abstract
A drug delivery device is provided comprising a dose setting mechanism having a spindle and a cartridge holder coupled to the dose setting mechanism. The cartridge holder comprising a cartridge having a movable bung at one end of the cartridge. The cartridge holder must be rotated before a dose may set with the dose setting mechanism.
Description
The present application is a U.S. National Phase Application pursuant to 35 U.S.C. §371 of International Application No. PCT/EP2010/057473 filed May 28, 2010, which claims priority to U.S. Provisional Patent Application No. 61/182,828 filed on Jun. 1, 2009 and European Patent Application No. 09009052.3 filed on Jul. 10, 2009. The entire disclosure contents of these applications are herewith incorporated by reference into the present application.
The present patent application is generally directed to drug delivery devices. More particularly, the present patent application is generally directed to drug delivery devices, such as pen type drug delivery devices. Such devices provide for self administration of medicinal product from a multi-dose cartridge and permit a user to set the delivery dose. The present application may find application in both resettable (i.e., reusable) and non-resettable (i.e., non-reusable) type drug delivery devices. However, aspects of the invention may be equally applicable in other scenarios as well.
Pen type drug delivery devices have application where regular injection by persons without formal medical training occurs. This is increasingly common among patients having diabetes where self-treatment enables such patients to conduct effective management of their disease.
In certain types of medication delivery devices, such as pen type devices, cartridges of medication are used. These cartridges are housed in a cartridge holder or cartridge housing. Such cartridges include a bung or stopper at one end. At the other end of the cartridge, the cartridge may comprise a pierceable seal. To dispense a dose of medication from such a cartridge, the medication delivery device has a dose setting mechanism that uses a spindle to move in a distal direction towards the cartridge and to press a distal end of the spindle against the bung. This expels a certain set or preselected dose of medication from the cartridge. In order to insure dose accuracy, it is important that the distal end of the spindle remains on the bung of the cartridge before, during and after injection of a dose of medicament.
One perceived disadvantage of certain known medication delivery devices is that because of the various tolerance differences that may occur during manufacturing (e.g., tolerance differences that may arise during component molding) of the various parts making up the drug delivery device and the desire to not pre-load the bung axially in the assembled device, there may be a gap between the end of the spindle and the cartridge bung after the medication delivery device has been assembled. In other words, when initially assembled, the cartridge (and hence cartridge bung) may not be in contact with the distal end of the spindle. Therefore, if a user using the drug delivery device for the first time dials a dose, the actual dose received may be equal to the dialed dose less the initial gap between the distal end of the spindle and cartridge bung. The air gap between the cartridge bung and distal end of the spindle may be equivalent to a dose that causes the received dose that is outside preferred dose accuracy limits. For example, this air gap may be equivalent to the loss of between 0 and 10 units (i.e., 0-0.14 milliliters) of drug product on the first dose.
There is, therefore, a general need to take these perceived issues into consideration when designing either resettable or non-resettable drug delivery devices, such as pen type drug delivery devices.
It is an object of the present invention to provide an improved dose setting mechanism which is especially suitable for priming a drug delivery device and/or prevents use of the device prior to a priming step.
This object is solved by a device as defined in claims 1 and 10 which requires a rotational movement of a cartridge holder to prime the device and/or to bring the device in a condition allowing setting of a dose. Preferably, the condition allowing setting of a dose is the primed condition of the device.
According to a first embodiment, a drug delivery device comprises a dose setting mechanism comprising a spindle. A cartridge holder is coupled to the dose setting mechanism. The cartridge holder comprises a cartridge having a movable bung at one end of the cartridge. The cartridge holder is rotated before a dose may be set with the dose setting mechanism. Preferably, the cartridge holder must be rotated less than 360 degrees before a dose may be set with the dose setting mechanism.
In more detail, the cartridge holder must be rotated with respect to the dose setting mechanism before the dose may be set with the dose setting mechanism. Thus, rotation of the cartridge holder may prime the drug delivery device.
According to a preferred development of this embodiment, rotation of the cartridge holder moves the spindle into an abutting engagement with the bung of the cartridge.
It may be advantageous, if rotation of the cartridge holder enables a dose dial sleeve of the dose setting mechanism to rotate which allows a user of the dose setting mechanism to set the dose.
Preferably, after the cartridge holder is rotated, the cartridge holder is rotationally locked to the dose setting mechanism. This rotationally locking of the cartridge holder to the dose setting mechanism may be by way of a one way, non-return detent feature.
To facilitate use of the device, the cartridge holder provides a visual indication that the cartridge holder must be rotated before the dose may be set by the dose setting mechanism.
According to the present invention, the drug delivery device may either be a resettable drug delivery device or a not-resettable (disposable) drug delivery device.
The terms “drug” or “medicinal product” or “medicament”, as used herein, mean a pharmaceutical formulation containing at least one pharmaceutically active compound,
wherein in one embodiment the pharmaceutically active compound has a molecular weight up to 1500 Da and/or is a peptide, a proteine, a polysaccharide, a vaccine, a DNA, a RNA, a antibody, an enzyme, an antibody, a hormone or an oligonucleotide, or a mixture of the above-mentioned pharmaceutically active compound,
wherein in a further embodiment the pharmaceutically active compound is useful for the treatment and/or prophylaxis of diabetes mellitus or complications associated with diabetes mellitus such as diabetic retinopathy, thromboembolism disorders such as deep vein or pulmonary thromboembolism, acute coronary syndrome (AC S), angina, myocardial infarction, cancer, macular degeneration, inflammation, hay fever, atherosclerosis and/or rheumatoid arthritis,
wherein in a further embodiment the pharmaceutically active compound comprises at least one peptide for the treatment and/or prophylaxis of diabetes mellitus or complications associated with diabetes mellitus such as diabetic retinopathy,
wherein in a further embodiment the pharmaceutically active compound comprises at least one human insulin or a human insulin analogue or derivative, glucagon-like peptide (GLP-1) or an analogue or derivative thereof, or exedin-3 or exedin-4 or an analogue or derivative of exedin-3 or exedin-4.
Insulin analogues are for example Gly(A21), Arg(B31), Arg(B32) human insulin; Lys(B3), Glu(B29) human insulin; Lys(B28), Pro(B29) human insulin; Asp(B28) human insulin; human insulin, wherein proline in position B28 is replaced by Asp, Lys, Leu, Val or Ala and wherein in position B29 Lys may be replaced by Pro; Ala(B26) human insulin; Des(B28-B30) human insulin; Des(B27) human insulin and Des(B30) human insulin.
Insulin derivates are for example B29-N-myristoyl-des(B30) human insulin; B29-N-palmitoyl-des(B30) human insulin; B29-N-myristoyl human insulin; B29-N-palmitoyl human insulin; B28-N-myristoyl LysB28ProB29 human insulin; B28-N-palmitoyl-LysB28ProB29 human insulin; B30-N-myristoyl-ThrB29LysB30 human insulin; B30-N-palmitoyl-ThrB29LysB30 human insulin; B29-N-(N-palmitoyl-Y-glutamyl)-des(B30) human insulin; B29-N-(N-lithocholyl-Y-glutamyl)-des(B30) human insulin; B29-N-(ω-carboxyheptadecanoyl)-des(B30) human insulin and B29-N-(ω-carboxyheptadecanoyl) human insulin.
Exendin-4 for example means Exendin-4(1-39), a peptide of the sequence H-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2.
Exendin-4 derivatives are for example selected from the following list of compounds:
H-(Lys)4-des Pro36, des Pro37 Exendin-4(1-39)-NH2,
H-(Lys)5-des Pro36, des Pro37 Exendin-4(1-39)-NH2,
des Pro36 [Asp28] Exendin-4(1-39),
des Pro36 [IsoAsp28] Exendin-4(1-39),
des Pro36 [Met(O)14, Asp28] Exendin-4(1-39),
des Pro36 [Met(O)14, IsoAsp28] Exendin-4(1-39),
des Pro36 [Trp(O2)25, Asp28] Exendin-4(1-39),
des Pro36 [Trp(O2)25, IsoAsp28] Exendin-4(1-39),
des Pro36 [Met(O)14 Trp(O2)25, Asp28] Exendin-4(1-39),
des Pro36 [Met(O)14 Trp(O2)25, IsoAsp28] Exendin-4(1-39); or
des Pro36 [Asp28] Exendin-4(1-39),
des Pro36 [IsoAsp28] Exendin-4(1-39),
des Pro36 [Met(O)14, Asp28] Exendin-4(1-39),
des Pro36 [Met(O)14, IsoAsp28] Exendin-4(1-39),
des Pro36 [Trp(O2)25, Asp28] Exendin-4(1-39),
des Pro36 [Trp(O2)25, IsoAsp28] Exendin-4(1-39),
des Pro36 [Met(O)14 Trp(O2)25, Asp28] Exendin-4(1-39),
des Pro36 [Met(O)14 Trp(O2)25, IsoAsp28] Exendin-4(1-39),
wherein the group -Lys6-NH2 may be bound to the C-terminus of the Exendin-4 derivative;
or an Exendin-4 derivative of the sequence
H-(Lys)6-des Pro36 [Asp28] Exendin-4(1-39)-Lys6-NH2,
des Asp28 Pro36, Pro37, Pro38Exendin-4(1-39)-NH2,
H-(Lys)6-des Pro36, Pro38 [Asp28] Exendin-4(1-39)-NH2,
H-Asn-(Glu)5des Pro36, Pro37, Pro38 [Asp28] Exendin-4(1-39)-NH2,
des Pro36, Pro37, Pro38 [Asp28] Exendin-4(1-39)-(Lys)6-NH2,
H-(Lys)6-des Pro36, Pro37, Pro38 [Asp28] Exendin-4(1-39)-(Lys)6-NH2,
H-Asn-(Glu)5-des Pro36, Pro37, Pro38 [Asp28] Exendin-4(1-39)-(Lys)6-NH2,
H-(Lys)6-des Pro36 [Trp(O2)25, Asp28] Exendin-4(1-39)-Lys6-NH2,
H-des Asp28 Pro36, Pro37, Pro38 [Trp(O2)25] Exendin-4(1-39)-NH2,
H-(Lys)6-des Pro36, Pro37, Pro38 [Trp(O2)25, Asp28] Exendin-4(1-39)-NH2,
H-Asn-(Glu)5-des Pro36, Pro37, Pro38 [Trp(O2)25, Asp28] Exendin-4(1-39)-NH2,
des Pro36, Pro37, Pro38 [Trp(O2)25, Asp28] Exendin-4(1-39)-(Lys)6-NH2,
H-(Lys)6-des Pro36, Pro37, Pro38 [Trp(O2)25, Asp28] Exendin-4(1-39)-(Lys)6-NH2,
H-Asn-(Glu)5-des Pro36, Pro37, Pro38 [Trp(O2)25, Asp28] Exendin-4(1-39)-(Lys)6-NH2,
H-(Lys)6-des Pro36 [Met(O)14, Asp28] Exendin-4(1-39)-Lys6-NH2,
des Met(O)14 Asp28 Pro36, Pro37, Pro38 Exendin-4(1-39)-NH2,
H-(Lys)6-desPro36, Pro37, Pro38 [Met(O)14, Asp28] Exendin-4(1-39)-NH2,
H-Asn-(Glu)5-des Pro36, Pro37, Pro38 [Met(O)14, Asp28] Exendin-4(1-39)-NH2,
des Pro36, Pro37, Pro38 [Met(O)14, Asp28] Exendin-4(1-39)-(Lys)6-NH2,
H-(Lys)6-des Pro36, Pro37, Pro38 [Met(O)14, Asp28] Exendin-4(1-39)-(Lys)6-NH2,
H-Asn-(Glu)5 des Pro36, Pro37, Pro38 [Met(O)14, Asp28] Exendin-4(1-39)-(Lys)6-NH2,
H-Lys6-des Pro36 [Met(O)14, Trp(O2)25, Asp28] Exendin-4(1-39)-Lys6-NH2,
H-des Asp28 Pro36, Pro37, Pro38 [Met(O)14, Trp(O2)25] Exendin-4(1-39)-NH2,
H-(Lys)6-des Pro36, Pro37, Pro38 [Met(O)14, Asp28] Exendin-4(1-39)-NH2,
H-Asn-(Glu)5-des Pro36, Pro37, Pro38 [Met(O)14, Trp(O2)25, Asp28] Exendin-4(1-39)-NH2,
des Pro36, Pro37, Pro38 [Met(O)14, Trp(O2)25, Asp28] Exendin-4(1-39)-(Lys)6-NH2,
H-(Lys)6-des Pro36, Pro37, Pro38 [Met(O)14, Trp(O2)25, Asp28] Exendin-4(S1-39)-(Lys)6-NH2,
H-Asn-(Glu)5-des Pro36, Pro37, Pro38 [Met(O)14, Trp(O2)25, Asp28] Exendin-4(1-39)-(Lys)6-NH2;
or a pharmaceutically acceptable salt or solvate of any one of the afore-mentioned Exedin-4 derivative.
Hormones are for example hypophysis hormones or hypothalamus hormones or regulatory active peptides and their antagonists as listed in Rote Liste, ed. 2008, Chapter 50, such as Gonadotropine (Follitropin, Lutropin, Choriongonadotropin, Menotropin), Somatropine (Somatropin), Desmopressin, Terlipressin, Gonadorelin, Triptorelin, Leuprorelin, Buserelin, Nafarelin, Goserelin.
A polysaccharide is for example a glucosaminoglycane, a hyaluronic acid, a heparin, a low molecular weight heparin or an ultra low molecular weight heparin or a derivative thereof, or a sulphated, e.g. a poly-sulphated form of the above-mentioned polysaccharides, and/or a pharmaceutically acceptable salt thereof. An example of a pharmaceutically acceptable salt of a poly-sulphated low molecular weight heparin is enoxaparin sodium.
Pharmaceutically acceptable salts are for example acid addition salts and basic salts. Acid addition salts are e.g. HC1 or HBr salts. Basic salts are e.g. salts having a cation selected from alkali or alkaline, e.g. Na+, or K+, or Ca2+, or an ammonium ion N+(R1)(R2)(R3)(R4), wherein R1 to R4 independently of each other mean: hydrogen, an optionally substituted C1-C6-alkyl group, an optionally substituted C2-C6-alkenyl group, an optionally substituted C6-C10-aryl group, or an optionally substituted C6-C10-heteroaryl group. Further examples of pharmaceutically acceptable salts are described in “Remington's Pharmaceutical Sciences” 17. ed. Alfonso R. Gennaro (Ed.), Mark Publishing Company, Easton, Pa., U.S.A., 1985 and in Encyclopedia of Pharmaceutical Technology.
Pharmaceutically acceptable solvates are for example hydrates.
According to another embodiment of the present invention, a priming mechanism for a drug delivery device comprises a dose setting mechanism. The dose setting mechanism comprises a spindle and a dose dial sleeve. A cartridge holder comprises a cartridge comprising a movable bung and a pierceable seal. A coupling part connects the cartridge holder to the dose dial sleeve. A spindle nut, rotationally coupled to the coupling part, couples the cartridge holder to the spindle. When the cartridge holder is rotated with respect to the dose setting mechanism, the spindle nut is rotated and the coupling part moves the spindle into an abutting engagement with the bung. Thus, priming of the device is effected by a rotation of the cartridge holder.
In the priming mechanism the coupling part, which may comprise a thin metal pressing and/or a rigid coupling component, unlocks the dose dial sleeve so that the dose dial sleeve may be rotated to set a dose.
Preferably, the dose setting mechanism comprises at least one flexible locking element. When the cartridge holder is rotated, the coupling part also rotates to thereby release said flexible locking element and allowing the dose dial sleeve to rotate and allow a user of the medical delivery device to set a dose.
The spindle nut may further comprise a plurality of helical ramps. The plurality of helical ramps drive the spindle nut in a distal direction when the cartridge holder is rotated so that the spindle abuts a first surface of the bung.
These as well as other advantages of various aspects of the present invention will become apparent to those of ordinary skill in the art by reading the following detailed description, with appropriate reference to the accompanying drawings.
Exemplary embodiments are described herein with reference to the drawings, in which:
Referring to FIG. 1 , there is shown a drug delivery device 1 in accordance with an exemplary arrangement. The drug delivery device 1 comprises a housing having a first cartridge retaining part 2, and a dose setting mechanism 4. The drug delivery device may be a resettable drug delivery device (i.e., a reusable device) or alternatively a non-resettable drug delivery device (i.e., a non-reusable device). A first end of the cartridge retaining part 2 and a second end of the dose setting mechanism 4 are secured together by connecting features. For non-resettable devices, these connecting features would be permanent and non-reversible. For resettable devices, these connecting features would be releasable.
In this illustrated arrangement, the cartridge housing 2 is secured within the second end of the dose setting mechanism 4. A removable cap 3 is releasably retained over a second end or distal end of a cartridge retaining part or cartridge housing. The dose setting mechanism 4 comprises a dose dial grip 12 and a window or lens 14. A dose scale arrangement 16 is viewable through the window or lens 14. To set a dose of medication contained within the drug delivery device 1, a user rotates the dose dial grip 12 such that a dialed dose will become viewable in the window or lens 14 by way of the dose scale arrangement 16.
The cartridge housing 6 has a distal end 23 and a proximal end 27. Preferably, the cartridge distal end 23 of the cartridge housing 6 comprises a groove 8 for attaching a removable needle assembly. However, other needle assembly connection mechanisms could also be used. If the drug delivery device 1 comprises a resettable device, the cartridge proximal end 27 is removably connected to the dose setting mechanism 4. In one preferred embodiment, cartridge housing proximal end 27 is removably connected to the dose setting mechanism 4 via a bayonet connection. However, as those of ordinary skill in the art will recognize, other types of removable connection methods such as threads, partial threads, ramps and detents, snap locks, snap fits, and luer locks may also be used.
As previously mentioned, the dose setting mechanism 4 of the drug delivery device illustrated in FIG. 2 may be utilized as a reusable drug delivery device. (i.e., a drug delivery device that can be reset) Where the drug delivery device 1 comprises a reusable drug delivery device, the cartridge 25 is removable from the cartridge housing 6. The cartridge 25 may be removed from the device 1 without destroying the device 1 by merely having the user disconnect the dose setting mechanism 4 from the cartridge housing 6.
In use, once the cap 3 is removed, a user can attach a suitable needle assembly to the groove 8 provided at the distal end 23 of the cartridge housing 6. Such needle assembly may be, for example, screwed onto a distal end 23 of the housing 6 or alternatively may be snapped onto this distal end 23. After use, the replaceable cap 3 may be used to re-cover the cartridge housing 6. Preferably, the outer dimensions of the replaceable cap 3 are similar or identical to the outer dimensions of the dose setting mechanism 4 so as to provide an impression of a unitary whole when the replaceable cap 3 is in position covering the cartridge housing 6 when the device is not in use.
In accordance with an exemplary arrangement, it may be beneficial to force a user to prime the drug delivery device of FIGS. 1 and 2 before the user dials and injects the first dose. In order to achieve this forced priming, as will be discussed in greater detail below, the drug delivery device 1 preferably forces a user to prime the device before they are permitted to select the first dose.
The process of forcing a user to prime the cartridge before they can select and dispense the first dose reduces a potential risk of injecting the prime dose. The idea of forced priming is particularly advantageous for disposable devices where there is oftentimes a gap between a distal end of the spindle and the cartridge bung before the device is used. This gap is a consequence of the tolerances associated with the assembled parts as well as the desire not to pre-load the bung axially in the assembled device.
If the device is designed so that this gap between a distal end of the spindle and the bung is removed (i.e., the device primed) before the user is able to dial a dose, then this is advantageous. In one preferred arrangement, the drug delivery device achieves this by the user rotating the cartridge holder relative to the housing in order to both prime the device and also to unlock the number sleeve so the user can subsequently rotate the dose dial sleeve to set the first dose. Preferably, once the device has been primed, the cartridge holder is locked rotationally and therefore cannot be rotated with respect to the dose setting mechanism.
In this preferred arrangement of drug delivery device 50, the dose setting mechanism 52 comprises various markings and indications along an outer surface 53. As can be seen in this arrangement, this marking comprises a marking indicating a locked position (i.e., un-primed state) 58 and a marking indicating an unlocked position (i.e., primed state) 62. In addition, various intermediate markings 59 are provided between the locked and unlocked position markings 58, 62, respectively.
In addition, the cartridge housing 54 comprises markings along its outer surface 63 and these markings include a positional indicator (i.e., an arrow) 56 that is used to indicate the relative position of the cartridge housing 54 with respect to the outer surface 53 of the dose setting mechanism 52. In this preferred arrangement, to prime the drug delivery device 50, the cartridge housing 54 is rotated in direction of arrow 60. Preferably, the cartridge housing 54 is rotated in the direction of arrow 60 with respect to the dose setting mechanism 52 so that the arrow 56 moves from the locked marking 58 and then aligns with the unlocked designation 62, as shown in FIG. 4 . In this final position, the drug delivery device 50 now resides in a primed state. That is, the spindle contained in the dose setting mechanism 52 now resides adjacent or abuts the bung provided in the cartridge of the cartridge housing 54. In addition, in a preferred arrangement, the drug delivery device 50 is also now unlocked so that the dose setting mechanism 52 may now be used to set a dose (as illustrated in FIG. 2 ). Most preferably, in this final position, the cartridge holder 54 is also rotationally locked and can therefore no longer be rotated with respect to the dose setting mechanism 52.
In this preferred arrangement, coupling part 80 comprises a thin metal pressing. However, those of ordinary skill will recognize that alternative coupling part arrangements may also be used. In this preferred arrangement, the coupling part 80 comprises a first set of axial projecting members 82 a, 82 b that project in an axial direction towards the distal end 69 of the cartridge housing 72. These projecting members 82 a, 82 b rotationally affix or engage a first portion 75 of the cavity 73. In addition, the coupling part 80 rotationally couples to a spindle nut and therefore a spindle of a dose setting mechanism and also acts upon a dose dial sleeve of the dose setting mechanism.
The coupling part 80 further comprises a second set of axial projecting members 86 a, 86 b. This second set of projecting members 86 a, 86 b extend in a proximal direction away from the proximal end 68 of the cartridge housing 72. This second set of projecting members 86 a, 86 b engage a portion of the dose setting mechanism, specifically an inner housing of the dose setting mechanism. As described below, the coupling part 80 further comprises two inwardly extending arms 84 a, 84 b that engage a spindle nut of the dose setting mechanism.
During assembly, the coupling part 80 will be positioned to slide into the cavity 101 of the housing portion 94 such that the second set of protruding members 86 a, 86 b of the coupling part 80 slide through recesses 96 a, 96 b of the housing portion 94, respectively. The second members 86 a, 86 b will then be positioned to reside over an external surface of the inner housing flexible elements 98 a, 98 b, respectively. In this position, the drug delivery device will not be primed but rather the dose dial sleeve 103 will be locked out and prevented from rotating. As such, a user of such a drug delivery device will be prevented from selecting a dose, that is, the user will be prevented from rotating the dose dial sleeve 103 before the user has under taken a drug delivery device priming step.
A spindle nut 114 is coupled to the coupling part 80 so that when the coupling part 80 rotates the spindle nut 114 rotates to drive a spindle 124 distally. As illustrated, this spindle nut 114 is circular in shape and comprises a first and a second helical ramp 116 a, 116 b. The spindle nut 114 further comprises a circular cavity having a male groove member 118. Once assembled, the spindle nut 114 is rotationally coupled to the coupling part 80 so that when a cartridge holder is coupled to a dose setting member and the cartridge holder is rotated, the spindle nut 114 rotates along with the cartridge holder. The first and second helical ramps 116 a, 116 b serve to drive the spindle nut 114 in a distal direction (i.e., towards the injection site) when the cartridge holder is rotated. Where the spindle nut 114 is used in a non-resettable drug delivery device, these helical ramps lock the cartridge holder rotationally at the end of the priming step. However, where the spindle nut is used in a resettable drug delivery device, the helical ramps are detented so as to allow the cartridge housing 72 to be rotated back and removed to enable a new cartridge to be fitted.
The height of the helical ramps 116 a, 116 b help to offset any slack in the drive mechanism that drives the spindle of the dose setting mechanism forwards to dispense a dose. In this manner, rotating the cartridge holder is generally equivalent to pressing on a dose button of the dose setting mechanism so as to take up slack in the drive mechanism.
Because in one arrangement the spindle 124 is threaded to a portion of the drug delivery device, as the spindle nut 114 rotates, it advances the spindle 124 axially in the distal direction D2 128 so as to prime the drug delivery device. The rotation of the cartridge housing, as mentioned, also unlocks the dose dial sleeve 103 to allow a user to now set a first dose of medication for the drug delivery device.
Exemplary embodiments of the present invention have been described. Those skilled in the art will understand, however, that changes and modifications may be made to these embodiments without departing from the true scope and spirit of the present invention, which is defined by the claims.
Claims (5)
1. A priming mechanism for a drug delivery device said priming mechanism comprising:
a dose setting mechanism comprising a housing, spindle, a dose dial sleeve and at least one flexible locking element configured to engage with and lock out the dose dial sleeve to prevent it from rotating relative to the housing before the drug delivery device has been primed;
a cartridge holder, said cartridge holder comprising a cartridge, said cartridge comprising a movable bung near a proximal end of said cartridge;
a coupling part separate from either the cartridge holder or the dose setting mechanism and configured to engage and connect the cartridge holder to the dose setting mechanism such that the coupling part and cartridge holder are rotatably fixed to each other, the coupling part having at least one inwardly extending arm, where the coupling part is configured to be movable relative to the dose dial sleeve from an initial non-primed state,
a spindle nut separate from either the cartridge holder or the dose setting mechanism where the spindle nut is rotationally fixed to said coupling part through engagement with the at least one inwardly extending arm, said spindle nut is rotationally engaged with the spindle, where the coupling part, spindle nut and cartridge holder are rotationally fixed to each other so that the spindle nut and cartridge holder can rotate relative to the spindle when the cartridge holder is engage with the coupling part;
such that priming of the drug delivery device is initiated when said cartridge holder is rotated with respect to said dose setting mechanism, where the rotation of the cartridge holder causes the spindle nut to rotate with the cartridge holder relative to the spindle and relative to the dose setting mechanism thereby driving the spindle to move axially without rotation into an abutting engagement with said bung; and
where rotation of the cartridge holder relative to the dose setting mechanism rotates the coupling part relative to the at least one flexible locking element which releases the at least one flexible locking element from engagement with the dose dial sleeve allowing said dose dial sleeve to rotate and allowing a user of said medical delivery device to set a dose.
2. The priming mechanism of claim 1 wherein said coupling part unlocks said dose dial sleeve so that said dose dial sleeve may be rotated to set a dose.
3. The priming mechanism of claim 1 wherein said coupling part comprises a thin metal pressing.
4. The priming mechanism of claim 1 wherein said coupling part comprises a rigid coupling component.
5. The priming mechanism of claim 1 wherein said spindle nut further comprises a plurality of helical ramps, said plurality of helical ramps driving said spindle nut in a distal direction when said cartridge holder is rotated so that said spindle abuts a first surface of said bung.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/320,639 US9849244B2 (en) | 2009-06-01 | 2010-05-28 | Dose setting mechanism for priming a drug delivery device |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18282809P | 2009-06-01 | 2009-06-01 | |
EP09009052 | 2009-07-10 | ||
EP09009052 | 2009-07-10 | ||
EP09009052.3 | 2009-07-10 | ||
PCT/EP2010/057473 WO2010139634A1 (en) | 2009-06-01 | 2010-05-28 | Dose setting mechanism for priming a drug delivery device |
US13/320,639 US9849244B2 (en) | 2009-06-01 | 2010-05-28 | Dose setting mechanism for priming a drug delivery device |
Publications (2)
Publication Number | Publication Date |
---|---|
US20120172812A1 US20120172812A1 (en) | 2012-07-05 |
US9849244B2 true US9849244B2 (en) | 2017-12-26 |
Family
ID=42244292
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/788,683 Active 2033-02-14 US9950116B2 (en) | 2009-06-01 | 2010-05-27 | Dose setting mechanism for priming a drug delivery device |
US13/320,639 Active 2032-01-28 US9849244B2 (en) | 2009-06-01 | 2010-05-28 | Dose setting mechanism for priming a drug delivery device |
US15/926,400 Active 2032-07-07 US11471602B2 (en) | 2009-06-01 | 2018-03-20 | Dose setting mechanism for priming a drug delivery device |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/788,683 Active 2033-02-14 US9950116B2 (en) | 2009-06-01 | 2010-05-27 | Dose setting mechanism for priming a drug delivery device |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/926,400 Active 2032-07-07 US11471602B2 (en) | 2009-06-01 | 2018-03-20 | Dose setting mechanism for priming a drug delivery device |
Country Status (10)
Country | Link |
---|---|
US (3) | US9950116B2 (en) |
EP (1) | EP2437812B1 (en) |
JP (1) | JP5690335B2 (en) |
CN (1) | CN102448518B (en) |
AU (1) | AU2010255809B2 (en) |
BR (1) | BRPI1014730A2 (en) |
CA (1) | CA2762425A1 (en) |
DK (1) | DK2437812T3 (en) |
IL (1) | IL216481A (en) |
WO (1) | WO2010139634A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11433186B2 (en) | 2017-12-13 | 2022-09-06 | Regeneron Pharmaceuticals, Inc. | Devices and methods for precision dose delivery |
US11439758B2 (en) | 2019-06-05 | 2022-09-13 | Regeneron Pharmaceuticals, Inc. | Devices and methods for precision dose delivery |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003068290A2 (en) | 2002-02-11 | 2003-08-21 | Antares Pharma, Inc. | Intradermal injector |
EP3495009B1 (en) | 2005-01-24 | 2021-12-08 | Antares Pharma, Inc. | An injector with prefilled syringe |
WO2007131025A1 (en) | 2006-05-03 | 2007-11-15 | Antares Pharma, Inc. | Injector with adjustable dosing |
US8251947B2 (en) | 2006-05-03 | 2012-08-28 | Antares Pharma, Inc. | Two-stage reconstituting injector |
CA2718053C (en) | 2008-03-10 | 2016-09-27 | Antares Pharma, Inc. | Injector safety device |
JP5611208B2 (en) | 2008-08-05 | 2014-10-22 | アンタレス・ファーマ・インコーポレーテッド | Multiple dose injection device |
US8579865B2 (en) | 2009-03-20 | 2013-11-12 | Antares Pharma, Inc. | Hazardous agent injection system |
US9950116B2 (en) * | 2009-06-01 | 2018-04-24 | Sanofi-Aventis Deutschland Gmbh | Dose setting mechanism for priming a drug delivery device |
EP2292286A1 (en) * | 2009-09-07 | 2011-03-09 | Sanofi-Aventis Deutschland GmbH | Drive mechanism for a medication delivery device and medication delivery device |
EP2475411B1 (en) * | 2009-09-07 | 2014-12-31 | Sanofi-Aventis Deutschland GmbH | Drive mechanism for drug delivery device |
EP2482889B1 (en) * | 2009-09-30 | 2016-02-10 | Sanofi-Aventis Deutschland GmbH | Assembly for a drug delivery device |
CA2773011A1 (en) * | 2009-09-30 | 2011-04-07 | Sanofi-Aventis Deutschland Gmbh | Drug delivery device and drive member for a drug delivery device |
AR078457A1 (en) * | 2009-09-30 | 2011-11-09 | Sanofi Aventis Deutschland | DRIVING MECHANISM FOR A DRUG DISCHARGE DEVICE |
US9402960B2 (en) * | 2009-09-30 | 2016-08-02 | Sanofi-Aventis Deutschland Gmbh | Drive mechanism for a drug delivery device and use of a reset member for a drive mechanism |
TWI464002B (en) * | 2010-11-08 | 2014-12-11 | Shl Group Ab | Container holder assembly and medicament delivery device assembly |
WO2012127046A2 (en) | 2011-03-24 | 2012-09-27 | Sanofi-Aventis Deutschland Gmbh | Device and method for detecting an actuation action performable with a medical device |
CA2830002C (en) * | 2011-03-25 | 2019-03-19 | Sanofi-Aventis Deutschland Gmbh | Drug delivery device |
KR20140050010A (en) * | 2011-06-17 | 2014-04-28 | 사노피-아벤티스 도이칠란트 게엠베하 | Cartridge holder assembly for drug delivery devices |
US9220660B2 (en) | 2011-07-15 | 2015-12-29 | Antares Pharma, Inc. | Liquid-transfer adapter beveled spike |
US8496619B2 (en) | 2011-07-15 | 2013-07-30 | Antares Pharma, Inc. | Injection device with cammed ram assembly |
CN104582760A (en) * | 2012-01-25 | 2015-04-29 | 诺沃—诺迪斯克有限公司 | Drug delivery device with cartridge fixation feature |
EP2817042A1 (en) | 2012-02-24 | 2014-12-31 | Novo Nordisk A/S | Drug delivery device with cartridge snap holding feature |
KR20150003179A (en) | 2012-03-06 | 2015-01-08 | 안타레스 팔마, 인코퍼레이티드 | Prefilled syringe with breakaway force feature |
CN104519928B (en) | 2012-04-05 | 2017-09-22 | 赛诺菲-安万特德国有限公司 | pen-type injector |
CN104487114A (en) | 2012-04-06 | 2015-04-01 | 安塔雷斯药品公司 | Needle assisted jet injection administration of testosterone compositions |
RU2724011C1 (en) | 2012-04-13 | 2020-06-18 | Бектон, Дикинсон Энд Компани | Automated device for injections |
US9364610B2 (en) | 2012-05-07 | 2016-06-14 | Antares Pharma, Inc. | Injection device with cammed ram assembly |
DK2953667T3 (en) | 2013-02-11 | 2020-01-27 | Antares Pharma Inc | Needle-assisted jet injection device with reduced triggering power |
EP2968792B1 (en) | 2013-03-11 | 2019-05-15 | Antares Pharma, Inc. | Dosage injector with pinion system |
WO2014165136A1 (en) | 2013-03-12 | 2014-10-09 | Antares Pharma, Inc. | Constant volume prefilled syringes and kits thereof |
AU2014296217B2 (en) | 2013-08-02 | 2018-08-30 | Becton, Dickinson And Company | Injection pen |
EP3058970A1 (en) * | 2015-02-19 | 2016-08-24 | Sanofi-Aventis Deutschland GmbH | Data collection device for attachment to an injection device |
EP4316552A2 (en) | 2015-06-09 | 2024-02-07 | Sanofi-Aventis Deutschland GmbH | Data collection apparatus for attachment to an injection device |
CN107787234B (en) | 2015-07-01 | 2021-03-12 | 诺和诺德股份有限公司 | Piston washer for a drug delivery device and drug delivery device incorporating such a piston washer |
CN107708773B (en) | 2015-07-01 | 2020-10-30 | 诺和诺德股份有限公司 | Drug delivery device and method for assembling a drug delivery device |
JP7230527B2 (en) * | 2019-01-22 | 2023-03-01 | 京セラドキュメントソリューションズ株式会社 | Toner container and image forming apparatus |
Citations (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US533575A (en) | 1895-02-05 | wilkens | ||
US5092842A (en) * | 1987-05-08 | 1992-03-03 | Wilhelm Haselmeier Gmbh & Co. | Injection device with a cocking element and a second setting element |
US5226895A (en) * | 1989-06-05 | 1993-07-13 | Eli Lilly And Company | Multiple dose injection pen |
US5279586A (en) | 1992-02-04 | 1994-01-18 | Becton, Dickinson And Company | Reusable medication delivery pen |
US5304152A (en) | 1990-03-29 | 1994-04-19 | Bernard Sams | Dispensing device |
US5320609A (en) | 1992-12-07 | 1994-06-14 | Habley Medical Technology Corporation | Automatic pharmaceutical dispensing syringe |
US5383865A (en) | 1993-03-15 | 1995-01-24 | Eli Lilly And Company | Medication dispensing device |
US5480387A (en) | 1991-07-24 | 1996-01-02 | Medico Development Investment Company | Injection device |
US5505704A (en) | 1993-04-02 | 1996-04-09 | Eli Lilly And Company | Manifold medication injection apparatus and method |
US5582598A (en) | 1994-09-19 | 1996-12-10 | Becton Dickinson And Company | Medication delivery pen with variable increment dose scale |
WO1997010864A1 (en) | 1995-09-19 | 1997-03-27 | Becton Dickinson And Company | Pen injector with cartridge loading mechanism |
US5626566A (en) | 1991-10-18 | 1997-05-06 | Novo Nordisk A/S | Large dose pen |
US5674204A (en) | 1995-09-19 | 1997-10-07 | Becton Dickinson And Company | Medication delivery pen cap actuated dose delivery clutch |
US5921966A (en) | 1997-08-11 | 1999-07-13 | Becton Dickinson And Company | Medication delivery pen having an improved clutch assembly |
WO1999038554A1 (en) | 1998-01-30 | 1999-08-05 | Novo Nordisk A/S | An injection syringe |
EP0937472A2 (en) | 1998-02-20 | 1999-08-25 | Becton Dickinson and Company | Repeat-dose medication delivery pen |
EP0937471A2 (en) | 1998-02-20 | 1999-08-25 | Becton Dickinson and Company | Medication delivery pen |
EP0937476A2 (en) | 1998-02-23 | 1999-08-25 | Becton, Dickinson and Company | Low-cost medication delivery pen |
WO2001010484A1 (en) | 1999-08-05 | 2001-02-15 | Becton, Dickinson And Company | Medication delivery pen |
US6193698B1 (en) | 1997-07-18 | 2001-02-27 | Disetronic Licensing Ag | System for locking a dosing button in a device for the adminstration of a product to be injected |
US6221046B1 (en) | 1995-03-07 | 2001-04-24 | Eli Lilly And Company | Recyclable medication dispensing device |
US20020052578A1 (en) | 2000-06-16 | 2002-05-02 | Moller Claus Schmidt | Injection device |
US20020120235A1 (en) | 2001-01-05 | 2002-08-29 | Christian Enggaard | Automatic injection device with reset feature |
US20030050609A1 (en) | 2000-03-24 | 2003-03-13 | Bernard Sams | One-way clutch mechanisms and injector devices |
US20040210199A1 (en) | 2001-05-16 | 2004-10-21 | Atterbury William Goodwin | Medication injector apparatus with drive assembly that facilitates reset |
US20040267207A1 (en) | 2003-03-03 | 2004-12-30 | Veasey Robert Frederick | Drive mechanisms suitable for use in drug delivery devices |
EP1541185A1 (en) | 2003-12-08 | 2005-06-15 | Novo Nordisk A/S | Automatic syringe with priming mechanism |
US20060153693A1 (en) | 2004-12-31 | 2006-07-13 | Patrick Fiechter | Administering apparatus comprising a service life timer |
US20070016142A1 (en) * | 2005-05-24 | 2007-01-18 | Stefan Burren | Dose metering mechanism for an injection device |
US20080027397A1 (en) * | 2003-08-12 | 2008-01-31 | Deruntz Otto D | Medication dispensing apparatus with triple screw threads for mechanical advantage |
WO2008074897A1 (en) | 2006-12-21 | 2008-06-26 | Novo Nordisk A/S | A syringe device |
US20080183139A1 (en) * | 2005-05-24 | 2008-07-31 | Stefan Burren | Dose setting mechanism for an injection device |
US20090275916A1 (en) | 2008-05-02 | 2009-11-05 | Sanofi-Aventis Deutschland Gmbh | Medication Delivery Device |
US20120172812A1 (en) * | 2009-06-01 | 2012-07-05 | Sanofi-Aventis Deutschland Gmbh | Dose setting mechanism for priming a drug delivery device |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3302462A (en) * | 1964-05-25 | 1967-02-07 | Dow Chemical Co | Pipetting device with stop mechanism |
DE4112259A1 (en) * | 1991-04-15 | 1992-10-22 | Medico Dev Investment Co | INJECTION DEVICE |
WO1992018180A1 (en) | 1991-04-22 | 1992-10-29 | Helldin Nils Goeran | A syringe, including a rod and a piston |
US5423752A (en) * | 1992-07-31 | 1995-06-13 | Habley Medical Technology Corporation | Variable proportion dispenser with cartridge replacement assembly |
DE9301334U1 (en) | 1993-02-01 | 1993-04-01 | Ing. Lang & Menke Gmbh, 5870 Hemer, De | |
US5411377A (en) | 1993-03-17 | 1995-05-02 | Houser; Michael P. | Mass displacement wave energy conversion system |
US5584815A (en) * | 1993-04-02 | 1996-12-17 | Eli Lilly And Company | Multi-cartridge medication injection device |
DK170604B1 (en) | 1993-12-07 | 1995-11-13 | Niels Erik Holm Aps | Metering unit for metering measured-off quantities of a liquid |
US5514097A (en) * | 1994-02-14 | 1996-05-07 | Genentech, Inc. | Self administered injection pen apparatus and method |
US5792117A (en) * | 1994-07-22 | 1998-08-11 | Raya Systems, Inc. | Apparatus for optically determining and electronically recording injection doses in syringes |
AU1860697A (en) * | 1995-09-08 | 1997-07-28 | Visionary Medical Products Corporation | Pen-type injector drive mechanism |
EP0848624B1 (en) * | 1996-07-05 | 2005-10-26 | Tecpharma Licensing AG | Injection device for injection of liquid |
ATE240755T1 (en) | 1997-07-14 | 2003-06-15 | Novo Nordisk As | CYLINDRICAL AMPOULE |
DE29818721U1 (en) | 1998-10-21 | 2000-03-02 | Medico Dev Investment Co | Injection device |
TW453884B (en) | 1999-09-16 | 2001-09-11 | Novo Nordisk As | Dose setting limiter |
CA2448726C (en) * | 2001-07-16 | 2012-01-31 | Eli Lilly And Company | Medication dispensing apparatus configured for rotate to prime and pull/push to inject functionality |
AU2003216521A1 (en) | 2002-03-18 | 2003-10-08 | Eli Lilly And Company | Medication dispensing apparatus with gear set for mechanical advantage |
US20040225258A1 (en) | 2002-03-30 | 2004-11-11 | Ernest Balestracci | Tamper evident overcap for a container |
DE10229138B4 (en) * | 2002-06-28 | 2008-01-31 | Tecpharma Licensing Ag | Product diverter with piston rod emergency reset |
DE10239784B4 (en) | 2002-08-29 | 2004-12-30 | Tecpharma Licensing Ag | Injection, infusion or inhalation device with dose display device |
EP1545663B1 (en) * | 2002-10-01 | 2006-08-30 | Becton Dickinson and Company | Medication delivery pen |
DE10302163A1 (en) | 2003-01-21 | 2004-07-29 | Tecpharma Licensing Ag | Unit administering medicament, includes inspection window showing section of scale against which internal mark shows dose set |
US7329241B2 (en) * | 2003-02-14 | 2008-02-12 | Valeant Pharmaceuticals North America | Drug delivery system for administering an adjustable preset dose |
GB0304822D0 (en) | 2003-03-03 | 2003-04-09 | Dca Internat Ltd | Improvements in and relating to a pen-type injector |
WO2004078293A1 (en) | 2003-03-05 | 2004-09-16 | 3Ip Co., Ltd. | Electronic dart game set and metod of assembling the same |
US20040186437A1 (en) * | 2003-03-20 | 2004-09-23 | Frenette Claude E. | Content-coded medical syringe, syringe set and syringe content identification method |
WO2005021072A1 (en) | 2003-09-03 | 2005-03-10 | Novo Nordisk A/S | Threaded rod and nut assembly |
DE20317377U1 (en) * | 2003-11-03 | 2005-03-17 | B D Medico S A R L | injection device |
DE10351597A1 (en) | 2003-11-05 | 2005-06-16 | Tecpharma Licensing Ag | Device and autoinjector for administration of an injectable product, useful in drug administration, e.g. for intravenous injection, comprises a housing, a product reservoir, piston, priming mechanism and metering element |
CN101022843B (en) | 2004-09-02 | 2010-12-29 | 塞诺菲-安万特德国有限公司 | Method of assembly of drug delivery devices |
EP2047878B1 (en) | 2004-12-01 | 2011-02-23 | Novo Nordisk A/S | Injection Device |
US9457154B2 (en) | 2005-01-25 | 2016-10-04 | Novo Nordisk A/S | Injection device with an end of dose feedback mechanism |
DE102005063311A1 (en) | 2005-02-23 | 2006-08-24 | Tecpharma Licensing Ag | Dispensing device for medical, diagnosic/cosmetic product, comprises indicator cylinder, housing, promoters for promoting the product relative to the housing, dosing equipment for adjusting product dose, and coupling elements |
WO2006089767A1 (en) | 2005-02-28 | 2006-08-31 | Novo Nordisk A/S | Dose setting mechanism for an injection device capable of presetting a maximum dose |
US20080221530A1 (en) | 2005-04-24 | 2008-09-11 | Novo Nordisk A/S | Injection Device With A GearBox |
DE102005022532A1 (en) * | 2005-05-17 | 2006-11-23 | Tecpharma Licensing Ag | Delivery device with forced priming |
DE102005032705B4 (en) * | 2005-05-24 | 2009-01-08 | Tecpharma Licensing Ag | Plastic spring |
JP4827922B2 (en) | 2005-07-27 | 2011-11-30 | ノボ・ノルデイスク・エー/エス | Dosing mechanism of an injection device that limits the setting of the dose corresponding to the remaining amount of the drug |
EP1965846A1 (en) | 2005-12-08 | 2008-09-10 | Eli Lilly And Company | Dose indicating assembly of a pharmaceutical injection device |
DE102005060928A1 (en) | 2005-12-20 | 2007-06-28 | Tecpharma Licensing Ag | Injection device with axially overlapping metering or display element |
CN101400394B (en) * | 2006-03-10 | 2012-07-04 | 诺沃-诺迪斯克有限公司 | An injection device having a gearing arrangement |
DE102006038123C5 (en) | 2006-08-14 | 2012-05-03 | Tecpharma Licensing Ag | Injection device with mechanical lock |
DE102007001432A1 (en) * | 2006-08-14 | 2008-02-21 | Tecpharma Licensing Ag | Blocking unit for dosing mechanism of injection device, has retaining unit acting together with dosing mechanism or dosing unit such that adjusting movement of mechanism or dosing unit in starting position of blocking unit is prevented |
PL3626289T3 (en) | 2006-09-15 | 2021-06-14 | Ypsomed Ag | Injection device comprising an improved delivery element |
GB2443390A (en) | 2006-11-03 | 2008-05-07 | Owen Mumford Ltd | Medicine delivery apparatus |
EP1923084A1 (en) | 2006-11-17 | 2008-05-21 | Sanofi-Aventis Deutschland GmbH | Dosing and drive mechanism for drug delivery device |
CA2681023C (en) | 2007-03-23 | 2015-11-03 | Novo Nordisk A/S | An injection device comprising a locking nut |
DE102007019124A1 (en) | 2007-04-23 | 2008-11-06 | Tecpharma Licensing Ag | Reversible metering device for an injection device |
DE102007026083A1 (en) | 2007-05-25 | 2008-11-27 | Haselmeier S.A.R.L. | injection device |
-
2010
- 2010-05-27 US US12/788,683 patent/US9950116B2/en active Active
- 2010-05-28 AU AU2010255809A patent/AU2010255809B2/en not_active Ceased
- 2010-05-28 CN CN201080024073.4A patent/CN102448518B/en active Active
- 2010-05-28 JP JP2012513563A patent/JP5690335B2/en active Active
- 2010-05-28 US US13/320,639 patent/US9849244B2/en active Active
- 2010-05-28 BR BRPI1014730A patent/BRPI1014730A2/en not_active IP Right Cessation
- 2010-05-28 EP EP10723579.8A patent/EP2437812B1/en active Active
- 2010-05-28 CA CA2762425A patent/CA2762425A1/en not_active Abandoned
- 2010-05-28 WO PCT/EP2010/057473 patent/WO2010139634A1/en active Application Filing
- 2010-05-28 DK DK10723579.8T patent/DK2437812T3/en active
-
2011
- 2011-11-20 IL IL216481A patent/IL216481A/en not_active IP Right Cessation
-
2018
- 2018-03-20 US US15/926,400 patent/US11471602B2/en active Active
Patent Citations (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US533575A (en) | 1895-02-05 | wilkens | ||
US5092842A (en) * | 1987-05-08 | 1992-03-03 | Wilhelm Haselmeier Gmbh & Co. | Injection device with a cocking element and a second setting element |
US5226895A (en) * | 1989-06-05 | 1993-07-13 | Eli Lilly And Company | Multiple dose injection pen |
US5304152A (en) | 1990-03-29 | 1994-04-19 | Bernard Sams | Dispensing device |
US5480387A (en) | 1991-07-24 | 1996-01-02 | Medico Development Investment Company | Injection device |
US5626566A (en) | 1991-10-18 | 1997-05-06 | Novo Nordisk A/S | Large dose pen |
US5279586A (en) | 1992-02-04 | 1994-01-18 | Becton, Dickinson And Company | Reusable medication delivery pen |
US5320609A (en) | 1992-12-07 | 1994-06-14 | Habley Medical Technology Corporation | Automatic pharmaceutical dispensing syringe |
US5383865A (en) | 1993-03-15 | 1995-01-24 | Eli Lilly And Company | Medication dispensing device |
US5505704A (en) | 1993-04-02 | 1996-04-09 | Eli Lilly And Company | Manifold medication injection apparatus and method |
US5582598A (en) | 1994-09-19 | 1996-12-10 | Becton Dickinson And Company | Medication delivery pen with variable increment dose scale |
US6221046B1 (en) | 1995-03-07 | 2001-04-24 | Eli Lilly And Company | Recyclable medication dispensing device |
US5674204A (en) | 1995-09-19 | 1997-10-07 | Becton Dickinson And Company | Medication delivery pen cap actuated dose delivery clutch |
WO1997010864A1 (en) | 1995-09-19 | 1997-03-27 | Becton Dickinson And Company | Pen injector with cartridge loading mechanism |
US5688251A (en) * | 1995-09-19 | 1997-11-18 | Becton Dickinson And Company | Cartridge loading and priming mechanism for a pen injector |
JPH11511364A (en) | 1995-09-19 | 1999-10-05 | ベクトン・ディキンソン・アンド・カンパニー | Pen syringe with cartridge loading mechanism |
US6193698B1 (en) | 1997-07-18 | 2001-02-27 | Disetronic Licensing Ag | System for locking a dosing button in a device for the adminstration of a product to be injected |
US5921966A (en) | 1997-08-11 | 1999-07-13 | Becton Dickinson And Company | Medication delivery pen having an improved clutch assembly |
WO1999038554A1 (en) | 1998-01-30 | 1999-08-05 | Novo Nordisk A/S | An injection syringe |
US6004297A (en) | 1998-01-30 | 1999-12-21 | Novo Nordisk A/S | Injection syringe |
US6235004B1 (en) | 1998-01-30 | 2001-05-22 | Novo Nordisk A/S | Injection syringe |
EP0937472A2 (en) | 1998-02-20 | 1999-08-25 | Becton Dickinson and Company | Repeat-dose medication delivery pen |
EP0937471A2 (en) | 1998-02-20 | 1999-08-25 | Becton Dickinson and Company | Medication delivery pen |
US5961495A (en) | 1998-02-20 | 1999-10-05 | Becton, Dickinson And Company | Medication delivery pen having a priming mechanism |
EP0937476A2 (en) | 1998-02-23 | 1999-08-25 | Becton, Dickinson and Company | Low-cost medication delivery pen |
US6248095B1 (en) | 1998-02-23 | 2001-06-19 | Becton, Dickinson And Company | Low-cost medication delivery pen |
WO2001010484A1 (en) | 1999-08-05 | 2001-02-15 | Becton, Dickinson And Company | Medication delivery pen |
US6936032B1 (en) * | 1999-08-05 | 2005-08-30 | Becton, Dickinson And Company | Medication delivery pen |
US20030050609A1 (en) | 2000-03-24 | 2003-03-13 | Bernard Sams | One-way clutch mechanisms and injector devices |
US6899698B2 (en) | 2000-03-24 | 2005-05-31 | Bernard Sams | One-way clutch mechanisms and injector devices |
US20020052578A1 (en) | 2000-06-16 | 2002-05-02 | Moller Claus Schmidt | Injection device |
US20040059299A1 (en) | 2000-06-16 | 2004-03-25 | Moller Claus Schmidt | Injection device |
US7241278B2 (en) | 2000-06-16 | 2007-07-10 | Novo Nordisk A/S | Injection device |
US20020120235A1 (en) | 2001-01-05 | 2002-08-29 | Christian Enggaard | Automatic injection device with reset feature |
US20040210199A1 (en) | 2001-05-16 | 2004-10-21 | Atterbury William Goodwin | Medication injector apparatus with drive assembly that facilitates reset |
US7195616B2 (en) * | 2001-05-16 | 2007-03-27 | Eli Lilly And Company | Medication injector apparatus with drive assembly that facilitates reset |
US20040267207A1 (en) | 2003-03-03 | 2004-12-30 | Veasey Robert Frederick | Drive mechanisms suitable for use in drug delivery devices |
US20050113765A1 (en) | 2003-03-03 | 2005-05-26 | Veasey Robert F. | Pen-type injector |
US20080027397A1 (en) * | 2003-08-12 | 2008-01-31 | Deruntz Otto D | Medication dispensing apparatus with triple screw threads for mechanical advantage |
US20070016143A1 (en) * | 2003-12-08 | 2007-01-18 | Novo Nordisk A/S | Medical delivery device having air shot means |
JP2007512932A (en) | 2003-12-08 | 2007-05-24 | ノボ・ノルデイスク・エー/エス | Pharmaceutical supply device having air shot means |
WO2005053778A1 (en) | 2003-12-08 | 2005-06-16 | Novo Nordisk A/S | A medical delivery device having air shot means |
EP1541185A1 (en) | 2003-12-08 | 2005-06-15 | Novo Nordisk A/S | Automatic syringe with priming mechanism |
US20060153693A1 (en) | 2004-12-31 | 2006-07-13 | Patrick Fiechter | Administering apparatus comprising a service life timer |
US20070016142A1 (en) * | 2005-05-24 | 2007-01-18 | Stefan Burren | Dose metering mechanism for an injection device |
US20080183139A1 (en) * | 2005-05-24 | 2008-07-31 | Stefan Burren | Dose setting mechanism for an injection device |
WO2008074897A1 (en) | 2006-12-21 | 2008-06-26 | Novo Nordisk A/S | A syringe device |
US20090275916A1 (en) | 2008-05-02 | 2009-11-05 | Sanofi-Aventis Deutschland Gmbh | Medication Delivery Device |
US20120172812A1 (en) * | 2009-06-01 | 2012-07-05 | Sanofi-Aventis Deutschland Gmbh | Dose setting mechanism for priming a drug delivery device |
Non-Patent Citations (4)
Title |
---|
European Search Report for European Patent App. No. 09009052, dated Jul. 6, 2010. |
International Preliminary Report on Patentability for International App. No. PCT/EP2010/057473, dated Dec. 6, 2011. |
International Search Report and Written Opinion for International App. No. PCT/EP2010/057473, completed Sep. 7, 2010. |
Office Action for Japanese Patent App. No. 2012-513563, dated Mar. 4, 2014. |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11433186B2 (en) | 2017-12-13 | 2022-09-06 | Regeneron Pharmaceuticals, Inc. | Devices and methods for precision dose delivery |
US11439758B2 (en) | 2019-06-05 | 2022-09-13 | Regeneron Pharmaceuticals, Inc. | Devices and methods for precision dose delivery |
Also Published As
Publication number | Publication date |
---|---|
JP5690335B2 (en) | 2015-03-25 |
AU2010255809B2 (en) | 2014-11-13 |
US9950116B2 (en) | 2018-04-24 |
IL216481A (en) | 2015-06-30 |
IL216481A0 (en) | 2012-01-31 |
AU2010255809A1 (en) | 2011-12-22 |
EP2437812B1 (en) | 2018-01-10 |
US20120172812A1 (en) | 2012-07-05 |
WO2010139634A1 (en) | 2010-12-09 |
CN102448518A (en) | 2012-05-09 |
CN102448518B (en) | 2014-09-17 |
US20100324496A1 (en) | 2010-12-23 |
EP2437812A1 (en) | 2012-04-11 |
DK2437812T3 (en) | 2018-04-23 |
US11471602B2 (en) | 2022-10-18 |
BRPI1014730A2 (en) | 2016-04-12 |
US20180207364A1 (en) | 2018-07-26 |
CA2762425A1 (en) | 2010-12-09 |
JP2012528622A (en) | 2012-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9849244B2 (en) | Dose setting mechanism for priming a drug delivery device | |
US9408978B2 (en) | Dose setting mechanism for priming a drug delivery device | |
US9399099B2 (en) | Dose setting mechanism for a drug delivery device | |
US8790315B2 (en) | Dose setting mechanism for a drug delivery device | |
US9533100B2 (en) | Dose setting mechanism for priming a drug delivery device | |
US8795239B2 (en) | Biasing mechanism for a drug delivery device | |
US9138541B2 (en) | Drive mechanism for a drug delivery device |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PLUMPTRE, DAVID;DAVIES, JAMES;JONES, CHRISTOPHER;AND OTHERS;SIGNING DATES FROM 20120229 TO 20120302;REEL/FRAME:027851/0303 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 4 |